|
|
Volumn 28, Issue 30, 2010, Pages 4545-4546
|
|
Phase I studies of drug combinations
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 DEOXYRIBOSE;
CAPECITABINE;
FLUOROURACIL;
RIDAFOROLIMUS;
TEMSIROLIMUS;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
MAMMALIAN TARGET OF RAPAMYCIN;
PROTEIN KINASE INHIBITOR;
PROTEIN SERINE THREONINE KINASE;
RAPAMYCIN;
SIGNAL PEPTIDE;
ANGIOGENESIS;
ANTINEOPLASTIC ACTIVITY;
DRUG EFFECT;
DRUG SAFETY;
DRUG TARGETING;
EDITORIAL;
HUMAN;
MAXIMUM TOLERATED DOSE;
MULTIPLE CYCLE TREATMENT;
OPTIMAL DRUG DOSE;
PATIENT COMPLIANCE;
PHARMACODYNAMICS;
PRIORITY JOURNAL;
QUALITY OF LIFE;
DRUG ADMINISTRATION;
DRUG ANTAGONISM;
DRUG INTERACTION;
ENZYMOLOGY;
EVIDENCE BASED MEDICINE;
METABOLISM;
NEOPLASM;
NOTE;
PATHOLOGY;
PHASE 1 CLINICAL TRIAL;
TREATMENT OUTCOME;
ANGIOGENESIS INHIBITORS;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS, PHASE I AS TOPIC;
DEOXYCYTIDINE;
DRUG ADMINISTRATION SCHEDULE;
DRUG INTERACTIONS;
EVIDENCE-BASED MEDICINE;
FLUOROURACIL;
HUMANS;
INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS;
MAXIMUM TOLERATED DOSE;
NEOPLASMS;
PROTEIN KINASE INHIBITORS;
PROTEIN-SERINE-THREONINE KINASES;
SIROLIMUS;
TREATMENT OUTCOME;
|
|
EID: 78049489652
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2010.30.6282 Document Type: Editorial |
|
Times cited : (21)
|
|
References (8)
|
